Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForceTM Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden
Findings presented at the International VT Symposium and published simultaneously in Circulation.CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 11, 2025 /PRNewswire/ -- Field Medical, Inc. today announced that Circulation has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS), the first-in-human evaluation of its FieldForceTM Ablation System for ventricular tachycardia (VT). Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium).The FieldForceTM Ablation System by Field Medical: This next-generation PFA system is designed for transmural lesion creation, offering a novel approach to VT ablation.Results at Six MonthsVCAS is a prospective, multicenter feasibility trial evaluating the safety and performance of the FieldForce Ablation System in patients with VT. Unlike conventional approaches, the system delivers a proprietary high-voltage, short-pulse waveform designed to penetrate dense scar tissue while minimizing thermal injury.Key Findings:82% freedom from recurrent VT/VF or ICD therapy98% reduction in VT/VF burden (episodes)11.5% had a primary safety event with 0 therapy-related complications "While this remains an initial feasibility study, the six-month outcomes are highly encouraging. Achieving 82% freedom from recurrence and a 98% reduction in arrhythmia burden with a nonthermal, tissue-selective energy is a meaningful result in VT therapy. Importantly, this is the first time we've seen evidence that PFA can reach deep, transmural scar tissue in the ventricle, a long-standing challenge with existing energy sources," said Vivek Reddy, M.D., co-principal investigator, lead author, and electrophysiologist at Mount Sinai, New York. "These findings give me cautious optimism that with continued refinement, this approach could represent an important advance in the treatment of scar-related VT."With U.S. Food and Drug Administration's (FDA) Breakthrough Device designation and acceptance into the FDA Total Product Life Cycle (TAP) Pilot Program, Field Medical is advancing this program toward a pivotal trial and a rigorous evaluation of high-voltage focal PFA in VT."It is rare for initial feasibility data to be published in Circulation, and this underscores both the rigor and the significance of the work," said Steven Mickelsen, M.D., founder and chief technology officer of Field Medical. "Our mission has always been to unite scientific credibility with innovation. These findings mark an important milestone as we continue to evaluate pulsed field ablation for its potential to improve outcomes for patients with ventricular arrhythmias."Looking ahead, the company is evaluating additional applications of its FieldForce Ablation System beyond VT and expects to present initial feasibility findings in atrial fibrillation (AF) at a major scientific meeting in early 2026.About FieldForceTM Ablation SystemThe FieldForce Ablation System features a single-point contact force PFA catheter with an innovative design utilizing proprietary FieldBendingTM technology to deliver targeted, brief, high-intensity electric fields. This next-generation PFA technology was designed to deliver both precise targeted lesions and large volume transmural lesions in the ventricle.About Field Medical®, Inc.Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System integrates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication.For more information, visit www.fieldmedicalinc.com and follow us on LinkedInX, and YouTube.The FieldForceTM Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.Source:Reddy VY, et al. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial. Circulation. Published online ahead of print October 10, 2025. doi:10.1161/CIRCULATIONAHA.125.077025CONTACT: Holly Windler, 619.929.1275, holly.windler@gmail.comPhoto - https://mma.prnasia.com/media2/2792975/Field_Medical_FieldForce__Ablation_System_Next_generation_PFA.jpg?p=medium600Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
Field Medical, Inc. is making waves in the field of cardiac arrhythmia treatment with the announcement of impressive six-month outcomes from the first-in-human Ventricular Catheter Ablation Study (VCAS) of their FieldForceTM Ablation System. The findings, simultaneously presented at the prestigious International VT Symposium and published in the leading journal *Circulation*, demonstrate significant potential for this novel approach to treating ventricular tachycardia (VT).
The VCAS trial evaluated the safety and performance of the FieldForceTM Ablation System in patients suffering from VT, a dangerous heart rhythm disorder. Unlike traditional ablation methods that rely on heat or freezing to destroy problematic heart tissue, the FieldForceTM system utilizes pulsed field ablation (PFA), a next-generation technology that delivers short, high-voltage electrical pulses. This innovative approach is designed to create transmural lesions, effectively targeting and eliminating the source of VT while minimizing damage to surrounding healthy tissue.
The results after six months are highly encouraging. The study showed that 82% of patients treated with the FieldForceTM system experienced freedom from recurrent VT/VF (ventricular fibrillation) or the need for implantable cardioverter-defibrillator (ICD) therapy. Furthermore, there was a remarkable 98% reduction in VT/VF burden, meaning patients experienced significantly fewer episodes of these life-threatening arrhythmias. While the study reported an 11.5% rate of primary safety events, notably, there were no therapy-related complications observed.
Dr. Vivek Reddy, co-principal investigator and lead author of the study, emphasized the significance of these findings. "Achieving 82% freedom from recurrence and a 98% reduction in arrhythmia burden with a nonthermal, tissue-selective energy is a meaningful result in VT therapy," he stated. He further highlighted the system's ability to reach deep, transmural scar tissue in the ventricle, a long-standing challenge in VT treatment.
The FieldForceTM Ablation System's potential has also been recognized by the U.S. Food and Drug Administration (FDA), which has granted it Breakthrough Device designation and accepted it into the FDA Total Product Life Cycle (TAP) Pilot Program. This support will expedite the development and evaluation of the system, paving the way for a pivotal trial to further assess the high-voltage focal PFA approach in treating